Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Corcept Therapeutics (CORT) Stock Price
News articles about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a coverage optimism score of 0.01 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.002692996539 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Vacillating Stocks: Corcept Therapeutics Incorporated, (NASDAQ: CORT), Corning Incorporated, (NYSE: GLW) – StocksNewsPro (press release) (stocksnewspro.com)
- Corcept Therapeutics Incorporated (NASDAQ: CORT), Southwestern Energy Company (NYSE: SWN) – Another motive … – Production Investments (press release) (productioninvestments.com)
- Wiling Stocks: Corcept Therapeutics Incorporated, (NASDAQ: CORT), Twilio Inc., (NYSE: TWLO) – Global Export Lines (press release) (globalexportlines.com)
- $56.54 Million in Sales Expected for Corcept Therapeutics Incorporated (CORT) This Quarter (americanbankingnews.com)
- Corcept Therapeutics Incorporated (CORT) Is Attracting Massive Concentrations By Volume Analysis – Investing News Update (investingbizz.com)
CORT has been the topic of several research analyst reports. BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Piper Jaffray Companies set a $30.00 price target on Corcept Therapeutics and gave the company a “buy” rating in a report on Monday, February 5th. Zacks Investment Research cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Stifel Nicolaus decreased their target price on Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, February 5th. Finally, B. Riley assumed coverage on Corcept Therapeutics in a report on Thursday, March 8th. They issued a “buy” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $22.80.
Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported $0.17 EPS for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.02). Corcept Therapeutics had a return on equity of 53.35% and a net margin of 81.11%. The company had revenue of $53.30 million during the quarter, compared to the consensus estimate of $53.30 million. During the same period in the prior year, the business posted $0.04 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 123.9% compared to the same quarter last year. equities analysts predict that Corcept Therapeutics will post 0.96 EPS for the current year.
In related news, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $18.67, for a total value of $149,360.00. Following the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $149,360. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Renee D. Gala bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 7th. The stock was bought at an average cost of $15.51 per share, for a total transaction of $155,100.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $15,510. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 24,000 shares of company stock worth $407,520. 19.20% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Corcept Therapeutics (CORT) Stock Price” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-corcept-therapeutics-cort-stock-price/1958794.html.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.